Retatrutide and Tirzepatide: What's the Difference

TL;DR: Both are synthetic laboratory peptides in the incretin-agonist class. Tirzepatide (CAS 2023788-19-2) engages two receptors — GIP and GLP-1; retatrutide (CAS 2381089-83-2) adds a third, the glucagon receptor. The core difference is the number of receptor targets. In-vitro research use only.

Retatrutide and tirzepatide are two of the most-discussed compounds in the incretin class, and laboratories use both as reference agonists in metabolic receptor-signalling research. Both are synthetic lyophilised peptides, and both belong to the incretin-analogue family. What separates them is structural and functional: how many receptors the molecule binds, and which signalling pathways that engages in cell-based models. Below is a compact comparison by target, sequence class, CAS, and studied pathways — with no clinical interpretation.

What's the difference between retatrutide and tirzepatide?

The key distinction is the number of receptor targets. Tirzepatide is a dual agonist: one molecule activates the GIP receptor and the GLP-1 receptor. Retatrutide is a triple agonist: the same design is extended to a third target, the glucagon receptor. All three are class-B G-protein-coupled receptors (GPCRs), so in biochemical models they drive a similar cascade — but the selectivity profile and relative activity at each receptor differ between the two compounds.

Receptor targets and sequence class

By sequence class, both are synthetic single-chain peptides of roughly 39 amino-acid residues, each carrying a C20 fatty-diacid moiety. In research models this lipid feature is studied as the element that enables serum-albumin binding. Tirzepatide is engineered on the native GIP sequence, whereas retatrutide is further engineered so that glucagon-receptor agonism is added to its GIP and GLP-1 activity. That third target is the molecular dividing line between the "dual" and "triple" profiles.

Which signalling pathways are studied?

Because GLP-1, GIP and the glucagon receptor are all class-B receptors, agonism at each couples to Gs, activates adenylate cyclase and drives cyclic-AMP (cAMP) accumulation in cell-based models. Researchers additionally study β-arrestin recruitment and receptor-internalisation kinetics, which differ both between receptors and between compounds. Comparative panels typically measure:

• Receptor binding — affinity and competitive displacement at isolated GLP-1, GIP and glucagon receptors;
• cAMP reporter assays — magnitude and potency of the Gs-coupled response;
• β-arrestin reporter assays — signalling bias and recruitment differences;
• Receptor-selectivity panels — relative activity at each target in one system.

For retatrutide, those panels include the glucagon receptor as a third axis, which makes the compound a convenient benchmark when studying the glucagon arm's contribution to the overall metabolic signal in vitro.

Research context: how both compounds are used

In the laboratory, both peptides most often serve as reference agonists — control compounds with a known profile against which new molecules are calibrated or analytical systems are validated. Tirzepatide is the benchmark for a dual GIP/GLP-1 response; retatrutide, for three-receptor comparisons. Both are used strictly in cell-free and cell-based systems: receptor-reporter lines, membrane preparations and biochemical panels. Reconstitution, where performed, is a one-time preparation of an in-vitro working stock per institutional protocol.

Verification: purity and documentation

For comparative work, reagent quality matters as much as target identity. Both catalogue items ship at ≥99% HPLC-MS purity. We do not currently issue a third-party certificate of analysis, and would rather say so than imply one.

Catalogue items: retatrutide (10 mg, lyophilised, CAS 2381089-83-2) and tirzepatide (5 mg, lyophilised, CAS 2023788-19-2).

Research use only. Both compounds are research reagents intended solely for in-vitro laboratory research by qualified professionals. Not for human or animal consumption, and not for diagnostic, therapeutic or other medical use. This material is provided for reference and contains no dosing or use guidance.